Nothing Special   »   [go: up one dir, main page]

MX2017003525A - Abiraterone acetate formulation and methods of use. - Google Patents

Abiraterone acetate formulation and methods of use.

Info

Publication number
MX2017003525A
MX2017003525A MX2017003525A MX2017003525A MX2017003525A MX 2017003525 A MX2017003525 A MX 2017003525A MX 2017003525 A MX2017003525 A MX 2017003525A MX 2017003525 A MX2017003525 A MX 2017003525A MX 2017003525 A MX2017003525 A MX 2017003525A
Authority
MX
Mexico
Prior art keywords
methods
abiraterone acetate
acetate formulation
formulation
compositions
Prior art date
Application number
MX2017003525A
Other languages
Spanish (es)
Inventor
William Bosch H
Nemeth Paul
Murphy Maura
BHAMIDIPATI Satya
Coleman Jason
Hill Christopher
Norret Marck
callahan Matthew
Original Assignee
Iceutica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55533897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017003525(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/707,922 external-priority patent/US20150246060A1/en
Application filed by Iceutica Inc filed Critical Iceutica Inc
Publication of MX2017003525A publication Critical patent/MX2017003525A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)

Abstract

Pharmaceutical compositions, including unit dosage forms, comprising abiraterone acetate and methods for producing and using such compositions are described.
MX2017003525A 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use. MX2017003525A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052294P 2014-09-18 2014-09-18
US14/707,922 US20150246060A1 (en) 2013-03-15 2015-05-08 Abiraterone Acetate Formulation and Methods of Use
PCT/US2015/050889 WO2016044701A1 (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use

Publications (1)

Publication Number Publication Date
MX2017003525A true MX2017003525A (en) 2017-06-21

Family

ID=55533897

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003525A MX2017003525A (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use.

Country Status (17)

Country Link
EP (1) EP3193857A4 (en)
JP (1) JP2017528457A (en)
KR (2) KR102617537B1 (en)
CN (1) CN106687112A (en)
AP (1) AP2017009804A0 (en)
AU (1) AU2015317466A1 (en)
BR (1) BR112017003219A2 (en)
CA (1) CA2958316A1 (en)
CO (1) CO2017002472A2 (en)
EA (1) EA201790650A1 (en)
IL (1) IL250270B (en)
MD (1) MD20170048A2 (en)
MX (1) MX2017003525A (en)
PH (1) PH12017500239A1 (en)
SG (1) SG11201701139YA (en)
TN (2) TN2017000098A1 (en)
WO (1) WO2016044701A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3280448B1 (en) 2015-04-10 2020-12-30 Capsugel Belgium NV Abiraterone acetate lipid formulations
CN118766866A (en) 2017-04-07 2024-10-15 玛亚实验室公司 Methods for improving solubility and bioavailability of therapeutic agents
EP3914234A4 (en) * 2019-01-25 2022-09-14 Shenzhen Pharmacin Co., Ltd. Pharmaceutical compositions
AU2020232706A1 (en) 2019-03-06 2021-09-16 Propella Therapeutics, Inc. Abiraterone prodrugs
CN110742870B (en) * 2019-12-04 2021-04-20 武汉大学 Abiraterone acetate preparation and preparation method thereof
CN111110646A (en) * 2020-02-19 2020-05-08 纳兰迦(上海)生物医药科技有限公司 Prescription and preparation method of low-specification abiraterone acetate oral preparation
CN113384542B (en) * 2020-03-14 2024-03-29 鲁南制药集团股份有限公司 Tablet of steroid CYP17 inhibitor solid dispersion and preparation method thereof
BR112022021732A2 (en) * 2020-05-08 2022-12-06 Janssen Pharmaceutica Nv PROSTATE CANCER TREATMENTS WITH COMBINATIONS OF ABIRATERONE ACETATE AND NIRAPARIB
EP3944860A1 (en) 2020-07-30 2022-02-02 Galenicum Health S.L.U. Abiraterone for use in a method of treating cancer
EP4291159A1 (en) 2021-02-15 2023-12-20 Propella Therapeutics, Inc. Abiraterone prodrugs
KR20240044329A (en) 2022-09-28 2024-04-04 한미약품 주식회사 Oral composite tablet comprising abiraterone acetate and prednisolone
KR20240145412A (en) 2023-03-27 2024-10-07 한미약품 주식회사 Pharmaceutical formulation comprising abiraterone acetate and prednisolone and method for preparing same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA33292B1 (en) * 2009-04-24 2012-05-02 Iceutica Pty Ltd PRODUCTION OF NANOPARTICLES ENCAPSULATED FOR COMMERCIAL PURPOSES
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
WO2014009437A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Oxidation stability of abiraterone acetate
WO2014009434A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
CN102743393A (en) * 2012-07-27 2012-10-24 海南盛科生命科学研究院 Medicinal composition containing abiraterone acetate and preparation technology thereof
CA2907415C (en) * 2013-03-15 2022-04-05 Iceutica Inc. Abiraterone acetate formulation

Also Published As

Publication number Publication date
EP3193857A1 (en) 2017-07-26
KR102617537B1 (en) 2023-12-22
WO2016044701A1 (en) 2016-03-24
SG11201701139YA (en) 2017-03-30
KR20170070025A (en) 2017-06-21
CO2017002472A2 (en) 2017-07-11
CA2958316A1 (en) 2016-03-24
IL250270A0 (en) 2017-03-30
PH12017500239A1 (en) 2017-07-03
KR102491439B1 (en) 2023-01-25
AU2015317466A1 (en) 2017-02-23
EA201790650A1 (en) 2017-07-31
AP2017009804A0 (en) 2017-03-31
MD20170048A2 (en) 2017-08-31
TN2018000318A1 (en) 2020-01-16
JP2017528457A (en) 2017-09-28
CN106687112A (en) 2017-05-17
IL250270B (en) 2021-02-28
EP3193857A4 (en) 2018-04-11
KR20230014878A (en) 2023-01-30
TN2017000098A1 (en) 2018-10-19
BR112017003219A2 (en) 2017-11-28

Similar Documents

Publication Publication Date Title
PH12017500239A1 (en) Abiraterone acetate formulation and methods of use
MX2023008693A (en) Modulatory polynucleotides.
LT3224254T (en) Substituted indazoles, process for their preparation, pharmaceutical formulations containing them, and their use for the preparation of medicaments
EP3386484A4 (en) Compositions and methods for delivery of therapeutic agents
NZ712350A (en) Abiraterone acetate formulation
MY187540A (en) Compounds active towards bromodomains
IL273300A (en) High dosage valbenazine formulation and compositions, methods, and kits related thereto
HK1246189B (en) Complexes of abiraterone acetate, process for the preparation thereof and pharmaceutical compositions containing them
TN2015000411A1 (en) Ceftolozane antibiotic compositions
IN2014MU00303A (en)
EP3177286A4 (en) Compositions and methods for physiological delivery using cannabidiol
EP3093023A4 (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
EP3177271A4 (en) Liquid formulation compositions, medicament delivery devices, and methods of preparation and use thereof
IN2014CH00840A (en)
EP3139908A4 (en) Formulations and methods for vaginal delivery of antiprogestins
EP3151826A4 (en) Omega-3 compositions, dosage forms, and methods of use
EP3175851A4 (en) Use of butenylphthalide, usage method thereof and method for preparing same into pharmaceutical composition
MX2017001512A (en) Compounds active towards bromodomains.
GB201414271D0 (en) Composition for delivery of an active pharmaceutical substance and method of preparing same
MY180947A (en) Ceftolozane antibiotic compositions
IN2014CH01890A (en)